Roughly two months after detailing positive results related to its Tendyne transcatheter mitral valve replacement (TMVR) system, Abbott Laboratories is highlighting progress in the U.S. Specifically, the Abbott Park, Ill.-based company revealed the start of the pivotal clinical study in the U.S. with the Tendyne system for the treatment of mitral regurgitation (MR). Read More
